Eli Lilly’s experimental new weight loss drug is available through an early access program for eligible adults with obesity or overweight before approval.
- Retatrutide is an investigational once-weekly weight loss drug developed by Eli Lilly
- Phase 2 trials involving 338 adults with obesity achieving 24.2% average weight loss after 48 weeks
- Retatrutide is not FDA-approved, and clinical trials are ongoing to confirm effectiveness
Eli Lilly’s experimental new weight loss drug is gaining attention as a potential breakthrough in obesity treatment.
The early access program outlines specific eligibility criteria for patients seeking the therapy before approval, highlighting the innovative drug development.
Obesity rates continue to rise worldwide, increasing the demand for more effective weight management solutions.
According to the World Health Organization (WHO), more than 1 billion people globally are living with obesity, and many individuals struggle to achieve long-term weight loss through lifestyle changes alone (1✔ ✔Trusted Source
Obesity and overweight
Eli Lilly’s Expanded Access Program Offers Early Access Before Approval
Eli Lilly has introduced an expanded access program, also known as a “compassionate use” program, to provide its investigational weight loss injectable medication Retatrutide to eligible patients before regulatory approval.
Such programs are intended for patients with serious medical conditions who may not have suitable treatment options and allow access to promising therapies under controlled conditions.
Advertisement
Who Qualifies for Eli Lilly’s Experimental Weight Loss Drug?
Eligibility for Retratrutide early access under Eli Lilly’s expanded access (compassionate use) program is based on specific medical criteria.
- Adults aged 18 years and older
- Having refractory obesity, meaning they have not achieved meaningful weight loss despite receiving the highest approved doses of currently available obesity medications.
- Must also have at least two obesity-related health conditions, such as type 2 diabetes or heart disease.
- Must be unable to participate in an ongoing Retatrutide clinical trial.
Advertisement
Retatrutide: Eli Lilly’s Experimental Weight Loss Drug Showing Promise
Retatrutide is an investigational once-weekly weight loss injectional drug developed by Eli Lilly and studied as a potential next-generation obesity treatment.
It is a triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors to regulate appetite, metabolism, and weight control.
Ongoing Phase 3 clinical trials are evaluating Retatrutide’s safety and efficacy in obesity, type 2 diabetes, obstructive sleep apnea, and cardiovascular and metabolic conditions.
The drug is not yet approved and cannot be marketed for human use (2✔ ✔Trusted Source
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Advertisement
Retatrutide Clinical Trials: Evaluating Safety, Weight Loss, and Benefits
Retatrutide clinical trials are assessing the safety and effectiveness in people with obesity and related metabolic conditions.
TRIUMPH is Eli Lilly’s Phase 3 clinical trial program designed to evaluate Retatrutide’s potential benefits across multiple obesity-related conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and knee osteoarthritis pain.
TRIUMPH-2 enrolled 1,152 participants with type 2 diabetes and obesity or overweight, while TRIUMPH-3 included 1,949 adults with severe obesity and cardiovascular disease (3✔ ✔Trusted Source
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
The broader TRIUMPH program has enrolled more than 5,800 participants globally to evaluate Retatrutide as a future obesity treatment and weight management therapy.
Earlier Phase 2 clinical trials involving 338 adults with obesity showed promising weight loss results, with participants receiving the highest 12 mg dose achieving an average 24.2% reduction in body weight after 48 weeks, compared with 1.6% with placebo.
In ongoing Phase 3 TRIUMPH trials, researchers are further evaluating whether Retatrutide can deliver sustained weight reduction, metabolic improvements, and potential health benefits while monitoring its long-term safety and tolerability.
The results from these trials will help determine whether Retatrutide can move closer to regulatory approval as a future obesity medication (4✔ ✔Trusted Source
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
FDA Review and Retatrutide’s Path Toward Approval
Retatrutide is currently an investigational drug and has not received FDA approval for weight loss treatment.
Eli Lilly is conducting late-stage Phase 3 clinical trials to evaluate its safety and effectiveness in obesity and related health conditions.
The FDA will review clinical trial data on benefits, risks, and manufacturing quality before deciding whether Retatrutide can be approved for public use.
How Patients Can Seek Early Access to Retatrutide
Patients cannot directly apply for Retatrutide expanded access. A treating physician must request access from Eli Lilly on the patient’s behalf.
If approved, the program requires FDA authorization and Institutional Review Board (IRB) approval before the investigational treatment can be provided (5✔ ✔Trusted Source
Expanded access CLINICAL TRIALS
With rising obesity rates and challenges in maintaining weight loss through lifestyle changes alone.
New therapies like GLP-1-based weight loss drugs and investigational treatments such as Retatrutide could transform the future of obesity care.
“Where there is a will, there is a way,” and advances in medical science are creating new pathways for healthier lives.
Frequently Asked Questions
Q: What Is Retatrutide?
A: Retatrutide is an investigational once-weekly weight loss drug developed by Eli Lilly. It is a triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors to help regulate appetite, metabolism, and body weight. It is currently being studied in clinical trials and is not FDA-approved yet.
Q: How Does Retatrutide Work?
A: Retatrutide works by activating three key hormone pathways involved in blood sugar control, hunger regulation, and energy metabolism. By targeting GLP-1, GIP, and glucagon receptors, it may help reduce appetite, improve metabolic function, and promote weight loss.
Q: When Will Retatrutide Be Available?
A: Retatrutide is still undergoing Phase 3 clinical trials to evaluate its safety and effectiveness. The drug’s availability will depend on the results of these studies and FDA approval. No official launch date has been announced yet.
Q: Is GLP-3 the Same as Retatrutide?
A: No. GLP-3 is not the same as Retatrutide. Retatrutide is sometimes discussed as a triple agonist because it targets GLP-1, GIP, and glucagon receptors. There is currently no approved “GLP-3†weight loss drug; the term may be a misunderstanding or confusion with GLP-1-based therapies.
Q: Is Retatrutide Safe?
A: Retatrutide has shown promising safety and weight loss results in clinical trials, but its long-term safety is still being evaluated. Common side effects reported in studies include nausea, vomiting, diarrhea, and other gastrointestinal symptoms. It cannot be considered fully approved or widely available until regulatory reviews are completed.
References:
- Obesity and overweight – (https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
- Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C – (https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional)
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) – (https://clinicaltrials.gov/study/NCT05929079)
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) – (https://clinicaltrials.gov/study/NCT05882045)
- Expanded access CLINICAL TRIALS – (https://www.lilly.com/science/clinical-trials/expanded-access)
Source-Medindia